| Sep 20 |
Regeneron/Sanofi Dupixent endorsed in EU for eosinophilic esophagitis for children
|
| Sep 20 |
Sanofi Sarclisa combo gains approval as first-line multiple myeloma treatment
|
| Sep 20 |
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
|
| Sep 20 |
Sanofi (SNY) ECTRIMS 2024 Investor Science Call Transcript
|
| Sep 20 |
Sanofi eyes approval after MS therapy slows disease progression by 31%
|
| Sep 20 |
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
|
| Sep 20 |
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
|
| Sep 20 |
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
|
| Sep 20 |
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
|
| Sep 20 |
Sanofi's Multiple Sclerosis Drug Slows Disability Progression in Phase 3 Study
|
